| Literature DB >> 30326632 |
Xin Ren1,2, Ruiyang Yin3, Dianzhi Hou4, Yong Xue5, Min Zhang6, Xianmin Diao7, Yumei Zhang8, Jihong Wu9, Jinrong Hu10, Xiaosong Hu11, Qun Shen12.
Abstract
Foxtail millet has relatively low starch digestibility and moderate glycemic index compared to other grains. Since there are still no clinical researches regarding its long-term effect on blood glucose, this self-controlled study was conducted to investigate the glucose-lowering effect of foxtail millet in free-living subjects with impaired glucose tolerance (IGT). Fifty g/day of foxtail millet was provided to enrolled subjects throughout 12 weeks and the related clinical parameters were investigated at week 0, 6 and 12, respectively. After 12 weeks of foxtail millet intervention, the mean fasting blood glucose of the subjects decreased from 5.7 ± 0.9 mmol/L to 5.3 ± 0.7 mmol/L (p < 0.001) and the mean 2 h-glucose decreased from 10.2 ± 2.6 mmol/L to 9.4 ± 2.3 mmol/L (p = 0.003). The intake of foxtail millet caused a significant increase of serum leptin (p = 0.012), decrease of insulin resistance (p = 0.007), and marginal reduction of inflammation. Furthermore, a sex-dependent difference in glucose-lowering effect of foxtail millet was observed in this study. Foxtail millet could improve the glycemic control in free-living subjects with IGT, suggesting that increasing the consumption of foxtail millet might be beneficial to individuals suffering from type 2 diabetes mellitus.Entities:
Keywords: blood glucose; dietary intervention; impaired glucose tolerance; whole foxtail millet
Mesh:
Substances:
Year: 2018 PMID: 30326632 PMCID: PMC6213109 DOI: 10.3390/nu10101509
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Participant flow diagram.
Figure 2Sex-dependent difference in daily intake of foxtail millet (A), fasting blood glucose (B), 2 h-glucose (C) and insulin resistance index (D) in subjects with impaired glucose tolerance. Difference between two different time points was examined using Bonferroni’s post-hoc test. All statistical tests were 2-sided, and * p < 0.05 and ** p < 0.01 were considered statistically significant.
T Metabolic characteristics of subjects during study period 1.
| Indices | Week 0 | Week 6 | Week 12 | |
|---|---|---|---|---|
|
| ||||
| FBG (mmol/L) | 5.7 ± 0.9 a | 5.4 ± 0.7 b | 5.3 ± 0.7 b | <0.001 |
| 2 h-Glucose (mmol/L) | 10.2 ± 2.6 a | 9.2 ± 2.8 b | 9.4 ± 2.3 b | 0.003 |
| FINS (pmol/L) | 94.7 ± 49.2 | 89.3 ± 52.4 | 84.0 ± 47.5 | 0.141 |
| 2 h-Insulin (pmol/L) | 805.3 ± 540.0 | 736.7 ± 581.1 | 759.1 ± 460.3 | 0.529 |
| Fasting C-peptide (pmol/L) | 657.4 ± 276.4 | 626.9 ± 289.0 | 598.9 ± 256.9 | 0.149 |
| Fructosamine (μmol/L) | 264.6 ± 25.4 | 268.7 ± 23.4 | 266.4 ± 26.1 | 0.293 |
| HOMA-IR | 3.6 ± 2.3 a | 3.1 ± 2.1 ab | 2.9 ± 1.7 b | 0.007 |
| HOMA-IS | 0.4 ± 0.2 | 0.4 ± 0.2 | 0.5 ± 0.6 | 0.085 |
| Blood lipid | ||||
| TC (mmol/L) | 5.2 ± 1.0 | 5.2 ± 1.0 | 5.2 ± 1.0 | 0.953 |
| TAG (mmol/L) | 2.0 ± 1.2 | 2.0 ± 1.2 | 2.1 ± 1.1 | 0.421 |
| HDL-C (mmol/L) | 1.2 ± 0.3 a | 1.3 ± 0.3 b | 1.3 ± 0.3 a | 0.044 |
| LDL-C (mmol/L) | 3.3 ± 0.9 | 3.4 ± 0.9 | 3.2 ± 0.9 | 0.056 |
| ApoA1 (mmol/L) | 1.6 ± 0.3 a | 1.6 ± 0.3 b | 1.6 ± 0.3 ab | 0.013 |
| ApoB (mmol/L) | 1.0 ± 0.3 | 1.1 ± 0.2 | 1.0 ± 0.2 | 0.140 |
| ApoA1/ApoB | 1.6 ± 0.6 | 1.6 ± 0.4 | 1.6 ± 0.5 | 0.684 |
| Blood pressure | ||||
| SBP (mmHg) | 125.0 ± 13.2 | 126.6 ± 14.5 | 128.3 ± 13.2 | 0.155 |
| DBP (mmHg) | 84.9 ± 8.5 a | 83.9 ± 8.4 a | 81.6 ± 7.8 b | 0.003 |
|
| ||||
| TNF-α (pg/mL) | 2.6 ± 5.5 | 1.3 ± 0.6 | 1.4 ± 0.5 | 0.088 |
| IL-6 (pg/mL) | 6.2 ± 9.4 a | 4.2 ± 5.3 b | 4.8 ± 5.5 ab | 0.084 |
|
| ||||
| Leptin (ng/mL) | 8.3 ± 6.4 a | 9.0 ± 6.1 ab | 9.6 ± 7.0 b | 0.012 |
| Adiponectin (ug/mL) | 2.1 ± 1.6 | 1.8 ± 1.6 | 1.8 ± 2.1 | 0.301 |
| GLP-1 (pg/mL) | 23.6 ± 6.1 | 23.9 ± 7.0 | 24.8 ± 9.0 | 0.437 |
|
| ||||
| Weight (kg) | 69.1 ± 11.6 a | 69.4 ± 11.7 ab | 68.2 ± 11.2 b | 0.004 |
| BMI | 26.0 ± 3.5 a | 25.8 ± 3.4 ab | 25.5 ± 3.2 b | <0.001 |
| Waist circumference (cm) | 90.3 ± 8.7 | 90.4 ± 9.5 | 89.6 ± 8.5 | 0.296 |
| Hip circumference (cm) | 100.3 ± 7.7 | 100.0 ± 7.1 | 100.0 ± 6.9 | 0.400 |
| Waist-hip ratio | 0.9 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.0 | 0.644 |
|
| ||||
| Body fat percentage (%) | 31.9 ± 8.1 a | 31.4 ± 8.0 ab | 30.9 ± 7.7 b | 0.132 |
| Body fat mass (kg) | 22.1 ± 7.1 a | 21.9 ± 7.2 ab | 21.1 ± 6.2 b | 0.086 |
| Fat-free mass (kg) | 47.0 ± 9.4 | 47.4 ± 9.2 | 47.2 ± 9.7 | 0.670 |
| Obesity degree | 110.0 ± 15.2 a | 110.0 ± 15.4 a | 108.3 ± 13.8 b | 0.005 |
| Muscle mass (kg) | 44.4 ± 9.1 | 44.8 ± 8.8 | 44.6 ± 9.3 | 0.677 |
| Protein (kg) | 10.5 ± 3.3 | 10.5 ± 3.1 | 10.6 ± 3.2 | 0.585 |
| Mineral (kg) | 2.6 ± 0.4 | 2.6 ± 0.4 | 2.6 ± 0.4 | 0.587 |
1 Data were represented as mean ± SD. FBG, fasting blood glucose; FINS, fasting insulin; TC, total cholesterol; TAG, total triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; SBP, systolic blood pressure; DBP, diastolic blood pressure; TNF-α, tumor necrosis factor-α; GLP-1, glucagon-like peptide-1; IL-6, interleukin-6; BMI, body mass index; SD, standard deviation; ANOVA, analysis of variance. 2 Significances of treatment effect were accessed by repeated measures ANOVA during the intervention period (week 0–week 6–week 12). a,b Data with the different superscript letters in the same row differ significantly (p < 0.05); Differences between two subgroups were examined using Bonferroni’s post-hoc test.